GMP on-site inspection for long-acting growth hormone of Jinsai Pharmaceutical Co., Ltd. this month

According to the website of the State Food and Drug Administration (CFDA) on May 21, the workshop of long-acting growth hormone (full name: polyethylene glycol recombinant human growth hormone injection) of Jinsai Pharmaceutical Co., Ltd., a subsidiary of Changchun Hi Tech Holding Co., Ltd., carried out GMP on-site inspection this month, and the last checkpoint before the product was put on the market was about to pass The long-term growth hormone is a kind of heavy-duty product that attracts the market's attention It was approved for production in January 2014, and now it is waiting for the GMP certification of the workshop to pass and put into production, so it can be put on the market Zhou Weiqun, the Secretary of the board of directors of Changchun hi tech, previously said that after the workshop obtained the GMP certificate, the company would immediately record the product price and strive to achieve the long-term listing in August According to Zhou Weiqun, in terms of price, long-term growth hormone will take a high-end line; in terms of marketing strategy, the product will be different from short-term growth hormone, which will be marketed separately, and the second tier cities will also arrange their own sales channels At the same time, the company has considered to invest in the construction of growth and development specialized hospital through financing means to provide channel construction for the listing of long-term growth hormone